Nicki has over 25 years’ experience in pharmaceutical and biotechnology R&D in a variety of scientific and corporate leadership roles. Most recently she was founding CEO of Amphista Therapeutics where she successfully steered and scaled the company through Series A and a $53M Series B round and closed two global Pharma collaborative deals within 3 years of spinning Amphista out from the University of Dundee and which together had a total deal value of ~$2.25Bn. 

As Chair of the Board of Nanna Therapeutics, together with the CEO, she steered the company's acquisition by Astellas. She was previously VP and Global Head of External Drug Discovery at F. Hoffmann-La Roche Ltd and was a member of the Neuroscience, Opthalmology and Rare Disease therapy area leadership team. 

Prior to that, she was Senior Director, Business Development for GSK’s Centre of Excellence for External Drug Discovery. Nicki’s additional biotech experience includes her role as founding CEO of VirionHealth and Head of Drug Discovery at Syntaxin Ltd (acquired by Ipsen). She holds a PhD in Cell Biology from University College London.